PLM 102
Alternative Names: PLD-102; PLM-102Latest Information Update: 08 Jun 2023
At a glance
- Originator PeLeMed
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Proto-oncogene protein c-ret modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and pharmacokinetics data from a preclinical study in Acute myeloid leukemia presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 03 Jun 2022 Preclinical trials in Acute myeloid leukaemia in South Korea (PO) on or before June 2022
- 03 Jun 2022 Pharmacodynamics data from a preclinical trial in Acute myeloid leukemia released by PeLeMed